News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Bitcoin climbed above $63,000 on Iran optimism and a tech rally, signaling improved investor risk appetite.
  • Phase 3 daraxonrasib doubled median survival in metastatic pancreatic cancer, creating a commercial opportunity and lifting the stock outlook.
  • Prime Medicine published early prime-editing clinical proof, offering asymmetric upside for equityholders if follow-up data confirm results.
  • Analysts proposed mid-term buy setups in Ares, Progressive, CMB.TECH and WhiteFiber, citing oversold conditions and potential upside.
  • A Ukrainian drone strike hit Temryuk port terminal, killing one and igniting fires, marking continued cross-border attacks on logistics targets.
  • Tamil Nadu regulator warned Tata Electronics after alleged wastewater seepage contaminated farm wells, threatening plant shutdown and supply-chain disruption.
  • Villagers in Albania clashed with private security over land sold for a Kushner-backed luxury resort, prompting EU scrutiny and legal challenges.

Latest Articles

Spain to Disburse 20 Million Euros to Victims of Cordoba High-Speed Train Crash

Spain to Disburse 20 Million Euros to Victims of Cordoba High-Speed Train Crash

Spain will allocate 20 million euros in compensation to those affected by the high-speed train crash near Adamuz that killed 45 people and injured more than 150. The government has outlined a structured, expedited payment plan for bereaved families and injured passengers amid heightened public scrutiny of transport safety and ministerial accountabi…

Credo Technology: A High-Conviction Dip Setup in AI Connectivity

Credo Technology: A High-Conviction Dip Setup in AI Connectivity

Credo Technology is a pure-play on high-speed connectivity inside AI data centers. After a sharp drawdown from its 52-week high, CRDO is now trading with a depressed RSI and below key moving averages, setting up a defined-risk dip-buy trade. The bull case leans on real operating momentum (including triple-digit revenue growth cited in recent covera…

Reddit Shares Slide 9% After Analyst Lowers 2026 Growth Outlook

Reddit Shares Slide 9% After Analyst Lowers 2026 Growth Outlook

Reddit Inc. shares dropped 9% on Tuesday following a cautious note from Cleveland Research analyst Ross Walthall that trimmed expectations for the platform's 2026 growth. The analyst cited weaker demand among new advertisers, reduced conviction around incremental spend from large U.S. partners and rising competitive pressures from short-form video …

World Cup draw drives surge in North America travel bookings despite safety concerns

World Cup draw drives surge in North America travel bookings despite safety concerns

Flight and hotel reservations for the 2026 FIFA World Cup in North America have risen sharply since the tournament match schedule was released in December, according to travel technology firm Amadeus. British travellers made 18% of the North America bookings, and 37% of reservations for the tournament period were placed in the month after the draw.…

KeyBanc Keeps Sector Weight on Avista After 2025 RFP Selections; Capital Plan, Rate Filing Highlight Path Forward

KeyBanc Keeps Sector Weight on Avista After 2025 RFP Selections; Capital Plan, Rate Filing Highlight Path Forward

KeyBanc has reaffirmed a Sector Weight rating on Avista (AVA) after the utility announced the winners of its 2025 Request for Proposals. The selected portfolio, which combines company-owned resources and power purchase agreements, is expected to drive $250 million to $350 million of incremental capital and may support an uplift to Avista's long-ter…

FDA Lifts Hold on Intellia’s Nerve-Disease Gene Therapy Trial, Enabling Restart of Patient Enrollment

FDA Lifts Hold on Intellia’s Nerve-Disease Gene Therapy Trial, Enabling Restart of Patient Enrollment

The U.S. regulator has lifted a clinical hold on Intellia Therapeutics’ late-stage trial of its CRISPR-based therapy, nexiguran ziclumeran, in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Intellia said it will resume patient enrollment as soon as possible after agreeing to enhanced safety monitoring measures. A…

HSBC Advises Investors to Maintain Aggressive Risk-On Posture

HSBC Advises Investors to Maintain Aggressive Risk-On Posture

HSBC is urging clients to stay positioned for further gains in risk assets, remaining overweight equities, high-yield credit, emerging-market debt and gold, while underweighting developed-market sovereigns, investment-grade credit and oil. The bank says geopolitics is secondary to U.S. rates, rates volatility and near-term growth expectations, and …